Search Results
Your search for The ASCO Post matches 391 pages
Showing 251 - 300Androgen-Deprivation Therapy May Increase Mortality in African American Men With Favorable-Risk Prostate Cancer
In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital (BWH) found that race significantly affected longevity by increasing the likelihood of death after receiving androgen-deprivation therapy. These findings were published by Kovtun et al in...
Sociodemographic and Clinical Predictors of Switching to Active Treatment From Observational Management in Low-Risk Prostate Cancer
Although active surveillance for patients with low-risk prostate cancer has become an increasingly acceptable strategy for disease management, many men opt for definitive therapies such as radical prostatectomy or radiation therapy. A new study of more than 2,200 patients with low-risk prostate...
Patients With Low-Risk Prostate Cancer on Active Surveillance Experience Good Quality of Life
Active surveillance has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low-risk prostate cancer. However, what is the impact of active surveillance on health-related quality of life in patients selected or opting for this...
Early Evidence of Anti–PD-1 Activity in Enzalutamide-Resistant Prostate Cancer
Restoring tumor-specific immunity is a treatment strategy that works well in melanoma and lung cancer patients. Now a new study out of the Oregon Health & Science University (OSHU) Knight Cancer Institute is reviving hope that the approach also may help men with life-threatening prostate...
PET/MRI: A One-Stop Imaging Test to Detect Prostate Cancer?
A University of Michigan study published by Piert et al in The Journal of Nuclear Medicine reported that the addition of molecular imaging based on F-18-choline positron-emission tomography (PET) improves the identification of significant prostate cancer over multiparametric prostate magnetic...
SNMMI 2016: PET/CT Imaging of Prostate Cancer With Specific Agent May Be an Accurate Prebiopsy/Preoperative Guide
With surgical removal at the frontline of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society of ...
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, on Prostate Cancer: Expert Perspectives on Four Studies
Toni K. Choueiri, MD, and Paul L. Nguyen, MD, both of the Dana-Farber Cancer Institute, discuss four key studies on high- and intermediate-risk prostate cancer, as well as localized disease (Abstracts 5001, 5003, 5023, and 5021).
Celestia S. Higano, MD, and Chris Parker, MD, on the PROMIS Study of Elevated PSA
Celestia S. Higano, MD, of the University of Washington, and Chris Parker, MD, of the Royal Marsden Hospital, discuss findings from this confirmatory study evaluating the accuracy of MRI and TRUS biopsy in men with an elevated PSA (Abstract 5000).
A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer
A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
AUA 2016: IsoPSA, a Novel, Structure-Based Biomarker Test for Prostate Cancer, Explored in a Multicenter Prospective Trial
A promising new test is detecting prostate cancer more precisely than current tests by identifying molecular changes in the prostate-specific antigen (PSA) protein, according to Cleveland Clinic research presented at the 111th Annual Scientific Meeting of the American Urological Association (AUA)...
AUA 2016: Relationship Between Testosterone Therapy and Prostate Cancer Explored
Men with low levels of the male sex hormone testosterone need not fear that testosterone replacement therapy will increase their risk of prostate cancer. This is the finding of an analysis of more than a quarter-million medical records of mostly white men in Sweden, research led by investigators at ...
AUA 2016: Cell-Cycle Progression Score Provides Significant Prognostic Information in Patients With Gleason Score < 7
Myriad Genetics announced results from a study of the prognostic information provided by its Prolaris test in patients with prostate cancer and a Gleason score < 7 at the 111th Annual Scientific Meeting of the American Urological Association (AUA) (Abstract MP02-20). Prolaris is a novel 46-gene ...
AUA 2016: BRCA Gene Mutations Associated With Increased Prostate Cancer Risk
Though predominantly known for their increased associations with breast cancer risk, germline mutations in the BRCA1 and BRCA2 genes are also associated with an increased susceptibility to other diseases, including prostate cancer. New data being presented during the 111th Annual Scientific Meeting ...
AUA 2016: Adjuvant Chemotherapy After Radical Prostatectomy May Benefit Men at High Risk for Relapse
Not all men with prostate cancer benefit from adjuvant chemotherapy after radical prostatectomy; however, African American men and men with a higher tumor stage may, according to a new U.S. Department of Veterans Affairs (VA) study (Abstract PI LBA 06) featured at the 111th Annual Scientific...
Stereotactic Body Radiation Therapy May Offer a Higher Cure Rate in Prostate Cancer Than More Traditional Approaches
A 5-year study published by Hannan et al in the European Journal of Cancer showed that stereotactic body radiation therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons...
Preclinical Studies Show Many Androgen-Deprivation Therapies May Suppress Adaptive Immune Responses
Prostate cancer patients and their doctors may want to think twice about the best timing for chemotherapy or radiation therapy in conjunction with a common nonsurgical treatment, based on international research findings led by UT Southwestern Medical Center investigators. Researchers using mouse...
Widely Cited Prostate-Specific Antigen Screening Publications Influence Biopsy Rates and Associated Complications
While absolute rates of biopsy and postbiopsy complications have decreased following several benchmark prostate-specific antigen (PSA) screening publications, the relative risk for each patient continues to increase, according to a new study by Mayo Clinic researchers. The study is the largest to...
Study Links Normal Stem Cells to Aggressive Prostate Cancer
A study that revealed new findings about prostate cells may point to future strategies for treating aggressive and therapy-resistant forms of prostate cancer. The study proved that the prostate basal cell layer contains adult stem cells, which possess a unique gene-expression profile resembling the ...
Light Reflectance Technique May Improve Ability to Remove Prostate Cancer During Surgery
Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85% accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery. These findings were reported...
GU Symposium 2016: Even After Antiandrogen Therapy, Docetaxel Remains Useful in Prostate Cancer
A study presented at the 2016 Genitourinary Cancers Symposium showed that 40% of patients with metastatic castration-resistant prostate cancer treated with docetaxel following abiraterone (Zytiga) had at least a 50% reduction in prostate-specific antigen (PSA), demonstrating the activity of...
GU Symposium 2016: New Blood Test Technology Shows Promise for Guiding Prostate Cancer Treatment Decisions
An early study suggests that an experimental blood test may help guide individualized decisions on the most appropriate treatments for patients with prostate cancer. The new noninvasive “liquid biopsy” scans the entire landscape of different kinds of cancer cells in blood and analyzes...
GU Symposium 2016: Regular Aspirin Use May Reduce Risk of Dying From Prostate Cancer
A large observational study has found that men who take aspirin regularly may have a lower risk of dying from prostate cancer. Men who took aspirin regularly after their prostate cancer diagnosis were less likely to die from the disease. However, aspirin did not affect the overall incidence of...
David Penson, MD, MPH, Receives $2 Million Research Award to Study Prostate Cancer
David Penson, MD, MPH, Professor of Urologic Surgery, Vanderbilt University Medical Center, Nashville, has received a $2 million research award from the Patient-Centered Outcomes Research Institute to study localized prostate cancer. Dr. Penson is also Director of the Vanderbilt Center for Surgical ...
California Stem Cell Agency Awards More than $40 Million in New Research Grants, including Funds for Prostate Cancer Research
The California Institute for Regenerative Medicine recently announced approval by the agency’s governing Board, the Independent Citizens Oversight Committee, of $40 million in funding for researchers at 10 institutions as part of its Early Translational IV Research awards. Among the institutions...
Drew Pinsky, MD, Elected to Prostate Cancer Foundation Board of Directors
The Prostate Cancer Foundation has announced that Drew Pinsky, MD, has been elected to the Foundation’s Board of Directors. Dr. Pinsky, a cancer survivor, is a Practicing Physician and a Member of the Staff of Huntington Memorial Hospital in Pasadena, California. He is also Assistant Clinical...
Peter Carroll, MD, MPH, Receives Grant for Early Detection of Prostate Cancer
The ZERO Cancer Research Fund has awarded the Jim Lafferty Memorial Research Grant in the amount of $45,000 to Peter Carroll, MD, MPH, of the University of California San Francisco, for the purpose of researching new and improved methods for early detection of prostate cancer. The grant is part of...
New ‘Condensed’ Grading System Shown to Be Accurate for Predicting Prostate Cancer Outcomes
Using information gleaned from more than 20,000 men, researchers at Johns Hopkins have affirmed the value of their alternative system for assessing the likelihood of growth and spread of prostate cancer. The new grading system, they said, is not only easier to use and understand, but also more...
Repeating Abnormal PSA Tests Reduces Number of Unnecessary Biopsies
For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer. However, in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies. Now, a new study from The Ottawa Hospital and...
Study Shows Abiraterone Acetate Is Useful Even in the Most Aggressive Prostate Cancers
In 1,048 prostate cancer patients previously treated with docetaxel, and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, even when a very high Gleason score indicated especially aggressive...
Majority of Men Who Forgo Aggressive Treatment for Prostate Cancer Are Not Monitored Appropriately
An increasing number of men diagnosed with low-risk prostate cancer are opting for active surveillance rather than aggressive treatment to avoid the debilitating potential side effects of surgery and radiation, such as erectile and urinary dysfunction. However, a new study by University of...
Vigorous Exercise and Healthy Habits May Dramatically Reduce Chance of Lethal Prostate Cancer for Men Over 60
A study that tracked tens of thousands of middle-aged and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may cut their chances of developing a lethal type of prostate cancer by up to 68%. While most prostate cancers are clinically indolent, a...
Two Studies Find Protein May Inhibit Prostate Cancer Bone Metastasis
Scientists from Lawrence Livermore National Laboratory (LLNL), in collaboration with researchers from University of California Merced and Davis, have found that a secreted protein predominantly expressed in bone inhibits prostate cancer metastasis to bone. Their research was published recently by...
Yoga Helps Maintain Quality of Life, May Lessen Side Effects in Men Undergoing Prostate Cancer Treatment
Men with prostate cancer who are undergoing radiation therapy can benefit from yoga, researchers at the Perelman School of Medicine at the University of Pennsylvania reported at the Society for Integrative Oncology’s 12th International Conference. The new, first-of-its-kind study, led...
Study Shows Wide Variation in Costs to Treat Low-Risk Prostate Cancer
University of California, Los Angeles (UCLA) researchers have described costs across the entire care process for low-risk prostate cancer—from the time a patient checks in for his first appointment to his post-treatment follow-up testing—using time-driven activity-based costing. For the ...
ASTRO 2015: The Addition of 24 Months of Daily Antiandrogen Therapy Improves Overall Survival Following Recurrence After a Radical Prostatectomy
Prostate cancer patients who face recurrence after radical prostatectomy have better overall survival rates with a combination of salvage radiation therapy and 24 months of antiandrogen therapy than with radiation therapy alone, according to research (Abstract LBA5) presented by Shipley et al on...
ASTRO 2015: A Shorter Radiation Therapy Schedule Can Be as Effective as a Conventional Schedule for Men With Low-Risk Prostate Cancer
Hypofractionated radiation therapy results in similar rates of cure and side effects compared to a longer treatment schedule for some men with low-risk prostate cancer, according to research (Abstract LBA6) presented by Lee et al October 19, 2015, at the American Society for Radiation Oncology...
ASTRO 2015: Genomic Classifier Appears to Predict Metastasis in Patients With Prostate Cancer Following Prostatectomy
For men with prostate cancer who have had a prostatectomy and salvage radiation therapy, analyzing their tumor genome provides clues as to whether their cancer will metastasize, thereby enabling clinicians to better personalize treatment options, according to research presented by Den et al...
ASTRO 2015: Hypofractionated Radiation Therapy May Be an Acceptable Treatment for Some Patients With Localized Prostate Cancer
Long-term patient-reported outcomes indicate that for some men with localized prostate cancer, hypofractionated intensity-modulated radiation therapy (IMRT) may be a reasonable treatment option and result in similar quality-of-life outcomes, compared to conventional radiation therapy, according to...
ASTRO 2015: Androgen-Deprivation Therapy for 2 Years After Radiotherapy Improves Disease-Free Survival in Patients With Advanced Prostate Cancer
A long-term follow-up of RTOG 9202 indicated that for patients with locally advanced prostate cancer, an additional 24 months of long-term androgen-deprivation therapy after radiation therapy plus short-term androgen-deprivation therapy improved disease-free survival by 60%, compared to patients...
Postprostatectomy Radiation Therapy Yields Low Toxicity and Favorable Patient-Reported Quality of Life
A prospective study of guideline-based, postoperative, image-guided intensity-modulated radiation therapy in patients with prostate cancer found low toxicity profiles and favorable patient-reported quality of life following treatment, with researchers concluding that toxicity and health-related...
Packaging Paclitaxel in Nanoparticles May Increase Drug Efficacy in Preclinical Models
Duke University researchers found that packaging the widely used cancer drug paclitaxel into nanoparticles more than doubled the drug’s effectiveness in destroying tumors in preclinical models. Their findings were published by Bhattacharyya et al in Nature Communications. Paclitaxel has been ...
Long Telomere Length Associated With Increased Lung Cancer Risk
A large-scale genetic study of the links between telomere length and risk for five common cancers found that long telomeres are associated with an increased risk of lung adenocarcinoma. No significant associations between telomere length and other cancer types or subtypes were observed. The study,...
Risk-Appropriate Therapies Now Commonplace in Prostate Cancer Treatment
After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at the University of California, San...
Study Identifies Mechanism Fueling Growth of Pancreatic and Prostate Cancer Cells
UCLA Jonsson Cancer Center scientists have identified a new mechanism that delivers a key substance that fuels the growth of pancreatic and prostate cancer cells, a finding that offers new hope in the fight against two of the deadliest forms of the disease. Their findings were published by...
DNA Repair Kinase Identified as Key Driver of Metastasis in Prostate Cancer
Researchers at Thomas Jefferson University reported finding a single molecule that appears to be the central regulator driving metastasis in prostate cancer. The study, published by Goodwin et al in Cancer Cell, offers a target for the development of a drug that could prevent metastasis in prostate ...
Study Finds Significant Drop in New Prostate Cancer Diagnoses
A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the United States declined 28% in the year following the draft recommendation from the U.S. Preventive Services Task Force (USPSTF) against routine prostate-specific antigen (PSA)...
Chemotherapy May Be Preferred Option for Some With Advanced Prostate Cancer
In a small clinical trial, scientists at Johns Hopkins Kimmel Cancer Center and James Buchanan Brady Urological Institute found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant. The...
Study Supports Early Intervention for Prostate Cancer Patients Who Experience Significant Emotional Distress
A study led by the University at Buffalo (UB) and Roswell Park Cancer Institute (RPCI) has identified beliefs and personality traits associated with higher levels of distress in patients with newly diagnosed prostate cancer. The findings support the value of emotional and informational support for...
Men With Asthma Less Likely to Develop Lethal Prostate Cancer
A recent analysis of a large observational study has revealed that men with a history of asthma are less likely than those without it to develop lethal prostate cancer, researchers at Johns Hopkins reported. These findings were published by Platz et al in the International Journal of Cancer....
